Bristol-Myers, ImClone Partnership No Longer Threatened

02/28/2002 | Wall Street Journal, The

Bristol-Myers Squibb reportedly has abandoned its threat to break off its marketing partnership with ImClone. Fears over ImClone's cancer drug Erbitux were quelled, company officials said, after a successful meeting Tuesday between ImClone and the FDA. A source said Bristol-Myers still wants to renegotiate the partnership, but an ImClone spokesman said, "We intend to work under the existing terms."

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care